List of Excipients in Branded Drug REMERON

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Organon USA Inc	REMERON	mirtazapine	0052-0109	HYDROXYPROPYL CELLULOSE
Organon USA Inc	REMERON	mirtazapine	0052-0109	HYPROMELLOSE
Organon USA Inc	REMERON	mirtazapine	0052-0109	LACTOSE
Organon USA Inc	REMERON	mirtazapine	0052-0109	MAGNESIUM STEARATE
Organon USA Inc	REMERON	mirtazapine	0052-0109	POLYETHYLENE GLYCOL 8000
Organon USA Inc	REMERON	mirtazapine	0052-0109	SILICON DIOXIDE
Organon USA Inc	REMERON	mirtazapine	0052-0109	STARCH, CORN

Remeron Excipient Strategy and Commercial Opportunities for Mirtazapine

Last updated: July 31, 2026

Remeron, the branded mirtazapine product, has limited remaining value as a conventional tablet franchise because mirtazapine is an established generic antidepressant with long-expired core composition and method-of-use exclusivity. Commercial opportunity now centers on differentiated excipient systems, orally disintegrating tablets, taste masking, pediatric or geriatric usability, supply-chain substitution, and reformulated products that can obtain new regulatory protection.

The highest-value excipient strategy is an orally disintegrating mirtazapine product that improves handling, disintegration, taste, moisture control, and dose flexibility without creating unnecessary manufacturing complexity. Remeron SolTab provides the closest reference formulation, but its formulation architecture can be redesigned with modern co-processed excipients, superior taste-masking systems, and improved packaging.

What is Remeron and which formulations contain mirtazapine?

Remeron is the U.S. brand name for mirtazapine, a tetracyclic antidepressant approved for major depressive disorder in adults. Mirtazapine acts primarily through central alpha-2 adrenergic antagonism and serotonin receptor modulation. Its pharmacologic profile is associated with sedation, increased appetite, and weight gain in some patients.

The historical Remeron portfolio included:

Product	Dosage form	Typical strengths	Commercial formulation role
Remeron	Immediate-release tablet	15 mg, 30 mg, 45 mg	Conventional swallowable tablet
Remeron SolTab	Orally disintegrating tablet	15 mg, 30 mg, 45 mg	Rapid oral disintegration and easier administration
Generic mirtazapine	Tablet and orally disintegrating tablet	15 mg, 30 mg, 45 mg	Current multisource market

The FDA labeling for Remeron describes conventional tablets containing standard tablet excipients, while Remeron SolTab uses an orally disintegrating technology with mannitol, microcrystalline cellulose, crospovidone, magnesium stearate, polysorbate 80, colloidal silicon dioxide, and flavoring components. The product also contains aspartame, which is relevant to phenylalanine labeling and formulation strategy (FDA, 2019a; FDA, 2019b).

What excipients are used in Remeron tablets?

Remeron tablet excipients support powder flow, compression, coating, tablet strength, and stability. The conventional tablet formulation includes excipients such as lactose monohydrate, corn starch, hydroxypropyl cellulose, colloidal silicon dioxide, magnesium stearate, hypromellose, titanium dioxide, and polyethylene glycol, depending on strength and coating presentation (FDA, 2019a).

Conventional Remeron tablet excipient functions

Excipient category	Representative excipients	Function
Diluent	Lactose monohydrate	Adds bulk and supports tablet weight
Binder	Hydroxypropyl cellulose	Improves granule and tablet cohesion
Disintegrant	Corn starch	Promotes tablet breakup after administration
Glidant	Colloidal silicon dioxide	Improves powder flow
Lubricant	Magnesium stearate	Reduces tooling friction
Film coating	Hypromellose, titanium dioxide, polyethylene glycol	Protects tablet and improves appearance
Color and identification	Titanium dioxide and coating system	Supports product differentiation

This formulation is conventional and readily reproducible by generic manufacturers. Its commercial barrier is therefore low unless a manufacturer creates a new product profile through excipient selection, delivery technology, packaging, or clinical usability.

What excipients are used in Remeron SolTab?

Remeron SolTab is the more commercially relevant reference product for excipient innovation. Its formulation is designed to disintegrate on the tongue without conventional water-assisted swallowing.

Remeron SolTab excipient architecture

Excipient	Primary role in an orally disintegrating tablet
Mannitol	Water-soluble filler, cooling mouthfeel, hardness control
Microcrystalline cellulose	Structural filler and compression aid
Crospovidone	Rapid wicking and tablet disintegration
Magnesium stearate	Lubrication
Colloidal silicon dioxide	Flow improvement and moisture management
Polysorbate 80	Wetting and dispersion support
Aspartame	Sweetener and taste correction
Flavoring	Reduction of bitter or medicinal taste

Mirtazapine has a bitter taste profile that makes taste masking central to SolTab development. A reformulator must manage the tradeoff between rapid disintegration and adequate taste control. High polymer levels, hydrophobic coatings, or excessive granulation can delay disintegration and impair the intended product profile.

How should an excipient strategy for mirtazapine be designed?

A commercial excipient strategy should begin with the target product profile rather than a simple substitution exercise. The main design options are conventional tablets, orally disintegrating tablets, multiparticulates, and potentially flexible-dose or pediatric presentations.

Conventional tablet strategy

For a standard mirtazapine tablet, the lowest-risk approach is a direct-compression or wet-granulation formulation using widely accepted excipients. The objective is cost, robustness, and supply security.

Potential formulation improvements include:

• Replacing lactose with mannitol, microcrystalline cellulose, dibasic calcium phosphate, or a co-processed filler.
• Using a multifunctional excipient to reduce the number of raw materials.
• Optimizing magnesium stearate concentration and blending time to prevent dissolution loss.
• Replacing corn starch with crospovidone, croscarmellose sodium, or sodium starch glycolate.
• Reducing dependence on titanium dioxide where market or regulatory restrictions make reformulation desirable.
• Using a moisture-resistant film coat and high-barrier blister packaging.

A lactose-free formulation could address patients with lactose intolerance and simplify positioning in certain markets. It would not, by itself, create strong patent protection because excipient substitutions are generally easy for competitors to design around.

Orally disintegrating tablet strategy

The ODT segment offers stronger commercial differentiation. A new mirtazapine ODT could use:

• Mannitol-based direct compression.
• Co-processed mannitol-cellulose systems.
• Crospovidone or croscarmellose sodium for fast disintegration.
• Ion-exchange resins for taste masking.
• Polymer-coated drug microparticles.
• Lipid-based taste-masking carriers.
• Cyclodextrin complexes where compatibility and loading permit.
• Flavor and sweetener systems with reduced aftertaste.
• Low-moisture packaging, including aluminum-aluminum blister systems.

The key performance targets are disintegration time, mechanical strength, friability, mouthfeel, taste, moisture uptake, and dose uniformity. The product must remain strong enough for commercial handling while breaking down rapidly in the oral cavity.

What formulation patents could protect a new mirtazapine product?

A new mirtazapine product would obtain the strongest potential formulation protection from a narrow combination of technical limitations. Broad claims covering mirtazapine with conventional excipients would face substantial validity and obviousness risk because the drug and common excipient classes are well known.

More defensible claim categories include:

1. A specific mirtazapine particle-size distribution combined with a defined ODT matrix.
2. A taste-masked mirtazapine particle coated with a particular polymer or lipid system.
3. A defined disintegration time and hardness range achieved through a specified excipient ratio.
4. A moisture-stabilized formulation with a particular water activity or packaging configuration.
5. A low-dose, pediatric, or geriatric dosage form with dose-flexible administration.
6. A formulation that reduces bitterness while maintaining a specified dissolution profile.
7. A manufacturing process that produces a uniform solid dispersion or coated microparticle.
8. A bilayer, multiparticulate, or orally dispersible dosage form with a distinct release profile.

The patent strategy should claim the formulation and the manufacturing process separately. Process claims can be valuable where the critical step is difficult to reproduce, such as drug coating, controlled granulation, drying, or particle engineering. The specification should contain broad excipient classes, narrower preferred combinations, analytical methods, comparative taste data, dissolution data, stability results, and manufacturing examples.

What is the Orange Book status of Remeron and mirtazapine?

Mirtazapine’s original FDA approval dates to 1996. The original brand exclusivity period and core patent protection have expired. The active commercial market is primarily generic.

Remeron and Remeron SolTab do not present the same Orange Book barrier as newer branded products. Any remaining listed patents, if applicable to a specific reference presentation, must be checked against the current FDA Orange Book because listing status can change through delisting, expiration, or product discontinuation. The principal commercial conclusion is unchanged: a new mirtazapine product cannot rely on the original Remeron exclusivity position and must create value through formulation, delivery, clinical differentiation, or branding (FDA, 2024).

When did mirtazapine lose exclusivity?

Mirtazapine lost practical market exclusivity in the early 2000s when generic products entered the U.S. market. Generic mirtazapine tablets and orally disintegrating tablets are approved through abbreviated new drug applications under the FDA’s generic-drug pathway.

The major exclusivity milestones are:

Milestone	Approximate timing	Commercial effect
Original U.S. approval of Remeron	1996	Established branded mirtazapine market
Core brand patent and regulatory protection	Late 1990s to early 2000s	Delayed generic entry
Generic tablet entry	Early 2000s	Removed practical tablet exclusivity
Generic ODT competition	Subsequent years	Reduced SolTab differentiation
Current market	Mature generic market	Low-cost supply and limited brand leverage

A reformulated mirtazapine product would need new intellectual property or regulatory positioning. The existence of old drug substance approval does not prevent approval of a new 505(b)(2) product, but the sponsor must establish the new product’s safety, efficacy, delivery characteristics, or formulation rationale.

Which companies are challenging or competing with Remeron?

Competition is primarily from generic pharmaceutical manufacturers rather than from biosimilar developers. Mirtazapine is a small molecule, so biosimilar regulation does not apply.

Representative competitive groups include:

• Large generic manufacturers with mirtazapine tablets.
• Manufacturers with orally disintegrating mirtazapine products.
• Contract development and manufacturing organizations supplying formulation or packaging services.
• Specialty pharmaceutical companies pursuing abuse-deterrent, pediatric, geriatric, or modified-delivery products.
• Excipient suppliers offering co-processed fillers, taste-masking polymers, superdisintegrants, and moisture-control systems.

The commercial threat to a new product is high if it is only a conventional immediate-release tablet. The threat is lower if the product combines clinically relevant administration advantages with enforceable formulation claims and reliable supply.

What generic entry risks exist for a new mirtazapine formulation?

A new product faces five principal generic-entry risks.

Formulation design-around

Generic manufacturers can often substitute one filler, binder, disintegrant, or lubricant for another while preserving bioequivalence. Claims directed only to broad excipient categories are vulnerable to design-around.

ANDA competition

If the product has no meaningful patent or regulatory exclusivity, an ANDA sponsor can enter with a pharmaceutically equivalent product. For an ODT, comparative dissolution and bioequivalence requirements may still be manageable where the active ingredient is well characterized.

Taste-masking replication

Taste-masking technologies can be difficult to protect if they depend on common polymers or standard coating methods. A defensible position requires a measurable technical effect tied to a defined formulation.

Manufacturing substitution

Generic manufacturers may use different equipment, granulation conditions, or excipient grades. Manufacturing claims should therefore focus on critical process parameters and product attributes rather than a single commercial machine.

Supply-based price erosion

Mirtazapine is a mature generic, and additional entrants can rapidly reduce pricing. A differentiated product needs a clear channel strategy, such as institutional use, long-term-care distribution, specialty pharmacy, or cash-pay consumer access.

How can excipient suppliers participate in the mirtazapine opportunity?

Excipient companies can capture value by supplying enabling technologies rather than commodity materials.

High-value excipient opportunities

Opportunity	Commercial rationale
Co-processed ODT excipients	Simplify manufacturing and improve tablet strength
Taste-masking polymers	Address mirtazapine bitterness
Ion-exchange resins	Bind drug and reduce oral exposure before swallowing
Direct-compression mannitol systems	Support rapid disintegration and acceptable mouthfeel
Low-peroxide excipients	Reduce oxidative degradation risk
Moisture-barrier films	Protect ODTs during storage
High-barrier blister systems	Improve stability and patient handling
Flavor systems	Improve adherence and repeat use
Pediatric-friendly excipients	Support age-appropriate dosage development

Excipient suppliers should generate formulation data using mirtazapine specifically. Generic platform data are less persuasive to a sponsor evaluating taste, dissolution, impurity formation, and stability for this drug.

What regulatory pathway is available for a new mirtazapine product?

A conventional generic tablet would generally use an ANDA if it meets the applicable reference-product and bioequivalence requirements. A differentiated formulation may use a 505(b)(2) new drug application if it relies partly on existing findings for mirtazapine but introduces a new dosage form, delivery system, route, or clinical use.

Potential 505(b)(2) opportunities include:

• A new orally disintegrating or oral-dispersible system.
• A pediatric formulation.
• A formulation with improved administration for dysphagia.
• A new delivery system with clinically meaningful pharmacokinetic benefits.
• A product designed for patients who cannot reliably swallow conventional tablets.

A new excipient itself generally does not create regulatory exclusivity. The sponsor must establish the safety of the formulation and the suitability of the excipient levels and route of administration. FDA’s Inactive Ingredient Database is an important screening tool, but listed use in another product does not eliminate the need for product-specific formulation and safety assessment (FDA, 2024b).

How strong is the patent estate for a new mirtazapine excipient product?

The legacy Remeron estate is weak as a barrier to generic entry. A newly developed mirtazapine formulation could have moderate to strong protection if it includes:

• A technically narrow formulation.
• Unexpected taste, stability, or disintegration results.
• A reproducible manufacturing process.
• Multiple independent claim types.
• Demonstrated clinical or adherence benefit.
• Broad geographic filings before public disclosure.

The strongest commercial package would combine composition-of-matter claims for the formulation, process claims, use claims where supportable, trademark protection, trade secrets for manufacturing parameters, and regulatory exclusivity under the selected FDA pathway.

What licensing deals and manufacturing partnerships could support mirtazapine reformulation?

A sponsor may license:

• ODT manufacturing technology.
• Taste-masking and microparticle platforms.
• Co-processed excipient systems.
• Blister and moisture-barrier packaging.
• Pediatric dosage-form technology.
• Regional commercialization rights.

A practical partnership structure would reserve formulation and patent ownership for the sponsor while granting the CDMO manufacturing rights. The agreement should address excipient source changes, second-source qualification, process validation, technical transfer, stability responsibility, regulatory variations, and freedom-to-operate indemnities.

For an established generic product, a licensing transaction is more likely to succeed when the technology solves a specific problem, such as bitterness, dose splitting, moisture sensitivity, or administration in dysphagic patients.

What commercial opportunities remain for Remeron and mirtazapine?

The most viable opportunities are differentiated products rather than another standard tablet.

Priority opportunities

1. A palatable ODT with robust moisture protection.
2. A lactose-free or low-excipient conventional tablet.
3. A pediatric or geriatric dosage form with dose flexibility.
4. A hospital and long-term-care product optimized for patients with swallowing difficulty.
5. A stable product using dual-source excipient procurement.
6. A 505(b)(2) product with clinically demonstrated administration or adherence benefits.
7. A branded generic supported by packaging, adherence services, and reliable supply.

Revenue exposure depends on the target market. Conventional mirtazapine tablets are subject to intense price competition. ODTs may sustain better pricing where payers, institutional buyers, or patients value ease of administration. The addressable market is largest for standard tablets, but the defensible margin opportunity is more likely in specialized dosage forms.

Key Takeaways

• Remeron is the branded mirtazapine product; the drug is now a mature generic active ingredient.
• Conventional tablet excipients provide limited differentiation and weak standalone patent value.
• Remeron SolTab is the more relevant reference for new excipient and dosage-form development.
• Taste masking, rapid disintegration, moisture control, and mechanical strength are the main technical challenges.
• A new product should pursue narrow formulation claims, process claims, and trade-secret manufacturing protection.
• Generic competition and price erosion make a standard tablet commercially unattractive without a cost or supply advantage.
• A 505(b)(2) strategy may support a differentiated ODT, pediatric product, or dysphagia-focused formulation.
• Biosimilar risk does not apply because mirtazapine is a small-molecule drug.
• Excipient suppliers have the greatest opportunity in enabling technologies, not commodity replacement.
• The strongest commercial concept is a clinically usable, taste-masked, moisture-stable mirtazapine ODT with defensible formulation IP.

FAQs About Mirtazapine Excipient and Reformulation Opportunities

Can lactose be removed from a mirtazapine tablet?

Yes. Lactose can potentially be replaced with mannitol, microcrystalline cellulose, dibasic calcium phosphate, or a co-processed filler. The replacement must preserve blend uniformity, hardness, disintegration, dissolution, and stability.

Is mirtazapine suitable for an orally disintegrating tablet?

Yes. Mirtazapine has an established ODT reference product. Development priorities are taste masking, rapid disintegration, moisture resistance, dose uniformity, and tablet robustness.

Does a new mirtazapine excipient create new patent protection?

Not automatically. Patent strength depends on the claimed formulation, measurable technical effect, manufacturing process, and evidence that the combination is not an obvious modification of known mirtazapine products.

Can an excipient supplier license a mirtazapine formulation platform?

Yes. A supplier can license a co-processed excipient, taste-masking technology, particle-engineering platform, or packaging system. The agreement should define ownership of drug-specific formulation data and improvements.

Would a new mirtazapine ODT qualify as a generic or a 505(b)(2) product?

The pathway depends on the product’s formulation and regulatory positioning. A pharmaceutically equivalent product may be eligible for an ANDA. A materially differentiated delivery system may require a 505(b)(2) application.

References

1. U.S. Food and Drug Administration. (2019a). Remeron (mirtazapine) tablets prescribing information. FDA/DailyMed.

2. U.S. Food and Drug Administration. (2019b). RemeronSolTab (mirtazapine) orally disintegrating tablets prescribing information. FDA/DailyMed.

3. U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. U.S. Food and Drug Administration. (2024b). Inactive ingredient database. FDA.

5. U.S. Food and Drug Administration. (2024c). Approved drug products and abbreviated new drug applications for mirtazapine. FDA Drugs@FDA.